Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Vayarin

Last reviewed on RxList: 8/1/2019
Vayarin Side Effects Center

Last reviewed on RxList 8/1/2019

Vayarin (lipirinen) is a medical food used to manage certain lipid imbalances associated with ADHD. Common side effects of Vayarin include:

  • abdominal pain,
  • dry and itchy skin,
  • tics,
  • nausea,
  • hyperactivity,
  • tantrum,
  • headache, and
  • insomnia

The usual dose of Vayarin is 2 capsules daily or as directed by a physician. Vayarin may interact with anticholinergic and cholinergic medications. Tell your doctor all medications and supplements you use. Vayarin is not recommended for use during pregnancy or breastfeeding as it is unknown how it would affect a pregnancy, or a nursing infant.

Our Vayarin (lipirinen) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

The abbreviated term ADHD denotes the condition commonly known as: See Answer
Vayarin Professional Information

3 pharmacies near 20147 have coupons for vayarin (Brand Names:Vayarin for 75-21.5-8.5MG)

Walgreens
Walgreens
$101.25

Est. Regular Price

$68.5

with free coupon

View Coupon
CVS Pharmacy
CVS Pharmacy
$101.25

Est. Regular Price

$71.5

with free coupon

View Coupon
Walmart Pharmacy
Walmart Pharmacy
$101.25

Est. Regular Price

$72.76

with free coupon

View Coupon

SIDE EFFECTS

Adverse Events

The adverse events of Vayarin® were evaluated in a randomized, double blind, placebo-controlled study of 15 weeks followed by an open label extension of an additional 15 weeks [38].

Adverse events reported during the course of the double-blind phase (table 2): 12 participants from the Vayarin® group and 5 participants from the placebo group were classified by the study physicians as suffering from treatment related, or probably related, adverse events (13 and 5 adverse events, respectively). There were no significant differences between the study groups in either the incidence or number of adverse events recorded (P = 0.848 and P = 0.982, respectively).

Adverse events reported during the course of the open-label extension (table 2): 5 participants reported 7 adverse events that were classified by the study physicians as related or probably related to the study treatment.

Table 2

Study design Double-blind study (4 capsules/day) Open-label extension (2 capsules/day)
Treatment Group Adverse event* Vayarin®
(n=137)
Placebo
(n=63)
Vayarin®
(n=150)
Gastrointestinal discomfort 6 4 4
Atopic dermatitis 1 0 0
SGOT value 1 0 0
Headache 0 1 1
Insomnia 0 0 1
Tics 1 0 0
High triglycerides 0 1 1
Nausea 1 0 0
Hyperactivity 1 0 0
Tantrnm 2 0 0

Table 2. Adverse events reported during the course of the double-blind and the open label phase.

*Judged by the study physicians as related or probably related to the study treatment

Drug Abuse

Vayarin® does not have any known drug abuse or withdrawal effects.

Read the entire FDA prescribing information for Vayarin (Lipirinen™ Capsules)

SLIDESHOW

ADHD Symptoms in Children See Slideshow
Related Resources for Vayarin

© Vayarin Patient Information is supplied by Cerner Multum, Inc. and Vayarin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors